^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    clonoSEQ

    Company:
    Adaptive Biotech
    9d
    ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Massachusetts General Hospital
    New P2 trial
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    10d
    MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma. (PubMed, Blood Adv)
    Longitudinal cfDNA analysis in ALR revealed clonal evolution during response and progression. This safe and active regimen is feasible as a time-limited initial therapy for MCL patients and warrants further evaluation in response-adapted strategy.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    clonoSEQ
    |
    Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    16d
    NGS-based monitoring of secondary acute lymphoblastic leukemia dynamics following lenalidomide maintenance in multiple myeloma patients. (PubMed, Leuk Lymphoma)
    We report on a series of three patients diagnosed with secondary acute lymphoblastic leukemia (sALL) following treatment for multiple myeloma (MM) where serial, commercially available, next-generation sequencing (NGS) based tracking of measurable residual disease (MRD) using the clonoSEQ assay provided valuable clinical insight. Each of the patients in this series had been treated for their MM with regimens that had included autologous stem cell transplantation following high dose melphalan chemotherapy and had been on maintenance treatment with the immunomodulatory drug lenalidomide for at least one year.
    Journal • Next-generation sequencing
    |
    clonoSEQ
    |
    lenalidomide • melphalan
    28d
    Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P1, N=27, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    clonoSEQ
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib) • Monjuvi (tafasitamab-cxix)
    28d
    MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, University of Arkansas | Initiation date: Oct 2025 --> Apr 2026
    Trial initiation date
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • melphalan • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Apr 2026 | Trial primary completion date: Oct 2025 --> Apr 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Brukinsa (zanubrutinib) • Monjuvi (tafasitamab-cxix)
    1m
    Real world outcomes of asciminib in relapsed/refractory Philadelphia chromosome positive B-ALL and blast Phase CML (ASH 2025)
    "While its efficacy is wellestablished in chronic-phase CML, the real-world data on its use in relapsed/refractory (r/r) B-ALL andblast-phase CML (CML-BP), particularly among patients who are ponatinib-refractory or those withcomplex resistance mutations remains underexplored.MethodsWe performed a retrospective analysis of adult patients with either B-ALL or CML-BP who receivedasciminib at our institution between November 1, 2021, and March 30, 2025. While higher dosing may be effectivein overcoming specific mutations, it could also contribute to the emergence of additional resistancemutations. These findings underscore the need for prospective studies to optimize dosing strategies,sequencing, and resistance monitoring."
    Clinical • Real-world evidence
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    clonoSEQ
    |
    Iclusig (ponatinib) • Scemblix (asciminib)
    1m
    Split dose R-CHOP mitigates toxicity while preserving dose intensity and response in frail elderly patients with diffuse large B cell lymphoma (DLBCL) - a Wisconsin oncology network (WON) study (ASH 2025)
    "Many OA receive non-anthracycline based treatment(tx), or attenuated regimens (i.e. R-miniCHOP) to avoid toxicity. Despite significant comorbidity and ahigh prevalence of factors associated with STox, events were less common than expected in this group.De-escalation of therapy appears feasible for pts with interim uMRD/PET- response, limiting toxicitywithout impacting long-term outcomes. These findings suggest that SD R-CHOP warrants further study infrail OA with DLBCL at high risk for STox."
    Clinical
    |
    clonoSEQ
    |
    Rituxan (rituximab) • vincristine
    1m
    BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=60, Recruiting, Christine Ryan | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Apr 2025
    Enrollment open • Trial initiation date
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • Brukinsa (zanubrutinib) • bendamustine • Truxima (rituximab-abbs) • sonrotoclax (BGB-11417)
    1m
    Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=53, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Apr 2028 --> Mar 2029 | Trial primary completion date: Apr 2028 --> Mar 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Truxima (rituximab-abbs) • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Hemady (dexamethasone tablets) • Erwinase (erwinia asparaginase) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    2ms
    GOLD: A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP (clinicaltrials.gov)
    P2, N=40, Recruiting, Danielle Wallace | Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    |
    clonoSEQ
    |
    Lunsumio (mosunetuzumab-axgb)
    2ms
    Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma (clinicaltrials.gov)
    P2, N=236, Active, not recruiting, Washington University School of Medicine | Trial completion date: Aug 2025 --> Aug 2026
    Trial completion date
    |
    clonoSEQ
    |
    lenalidomide • Ninlaro (ixazomib)